TVM Capital — Full Portfolio
7 tracked investments · listed companies and verified rows first
Access Vascular develops thrombus-evading intravascular catheters made from a proprietary biomaterial, offering an FDA-cleared PICC and the HydroMID peripherally inserted midline catheter to reduce vascular access complications.
BiotechHealthtechMedical DevicesNew MaterialsBedford, US
James Biggins(Chief Executive Officer, President and Founder)Dennis Byrne(Chief Commercial Officer)Scott Blood(VP of Regulatory and Quality)Katie Motherway(VP of Human Resources)Paul Sabin(Director)Joseph Pellegrino(Director)
Board seatLuc Marengere· per SEC Form D
Co-investorsTVM Capital Life ScienceGreen Park & Golf Ventures
BiotechCambridge, US
Christopher Schelling(Executive Officer, Director, Promoter)Harry S. Palmin(Executive Officer, Director, Promoter)
BoardCynthia Lavoie(Director)
Board seatHubert Birner· per SEC Form D · $15.7M raise · filed Oct 2017
BiotechDurham, US
Bernice Kuca(Executive Officer)Mathers P. Thomas(Executive Officer, Director)Nadia Rupniak(Executive Officer)Timothy C. Gupton(Executive Officer)
BoardJesse I. Treu(Director)inRichard J. Markham(Director)
Board seatLuc Marengere· per SEC Form D · $37.1M raise · filed Jan 2015
Co-investorsPappas CapitalDomain Associates
Developer of an oral small molecule targeting a mutation involved in acute myeloid leukemia, sarcomas, and gliomas; acquired by Eli Lilly.
Project-focused company developing an aurora kinase A inhibitor (AK-01) licensed from Lilly; acquired by Lilly ~1.5 years after TVM's investment.
Developer of lasmiditan, an oral 5-HT1F agonist for acute migraine treatment; IPO'd on Nasdaq and later acquired by Lilly for $960 million.
Egg Medical develops the EggNest, a scatter radiation shielding system designed to reduce radiation exposure for interventional fluoroscopy teams during cardiac catheterization and endovascular procedures.
HardwareHealthtechMedical DevicesArden Hills, US
Robert F. Wilson(Founder & Chief Executive Officer)inJohn Gainor(Co-founder & Chief Technology Officer)inScott Youngstrom(Chief Financial Officer)inGavin Philipps(Chief Commercial Officer)in
BoardMarc Riviere(Director)Luc Marengere(Director)
Co-investorsJStar Capital InvestmentsTVM Capital Life Science
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.